Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price
Complete. Here is the key summaryBank of America analyst Jason Gerberry maintains a Sell/Underperform rating on Exelixis with a $41 price target, citing underwhelming colorectal cancer data from the STELLAR-303 trial. The trial showed weak overall survival benefits in non-Latinx subgroups, raising competitive concerns and limiting commercial potential. Consequently, Gerberry forecasts modest U.S. peak sales of ~$300 million for zanza, keeping his outlook cautious despite the stock's recent 11% rise.
Exelixis, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities maintained a Sell rating on the stock and has a $41.00 price target.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Jason Gerberry has given his Sell rating due to a combination of factors related to Exelixis’s colorectal cancer program. He highlights that while the STELLAR-303 trial achieved overall survival in the full population, the non-Latinx minority subgroup failed to show a clear overall survival benefit, and its hazard ratio looks weaker than that of an existing regimen, raising doubts about the regimen’s competitive strength.
He argues that this muted signal could limit oncologists’ willingness to adopt the regimen, especially in a third-line-plus setting that is already small and crowded. As a result, he remains cautious on the commercial potential of zanza in colorectal cancer, keeps a modest U.S. peak sales forecast around $300 million for STELLAR-303, and therefore maintains an Underperform rating with a price objective below the current share price.
EXEL’s price has also changed moderately for the past six months – from $46.190 to $51.350, which is a 11.17% increase.